Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–91.
EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167-85.
Butt SRR, Satnarine T, Ratna P, Sarker A, Ramesh AS, Munoz C, et al. A systematic review on current trends in the treatment of chronic hepatitis b to predict disease remission and relapse. Cureus. 2022;14: e32247.
PubMed PubMed Central Google Scholar
Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis. 2021;8:2049936120985954.
CAS PubMed PubMed Central Google Scholar
Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs. 2003;12:683–8.
Article CAS PubMed Google Scholar
Cornberg M, Lok AS, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(‡). J Hepatol. 2020;72:539–57.
Article CAS PubMed Google Scholar
Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275–81.
Article CAS PubMed Google Scholar
Malcolm J, Falzone N, Lee BQ, Vallis KA. Targeted radionuclide therapy: New advances for improvement of patient management and response. Cancers (Basel). 2019;11(2):268.
Widel M. Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy? Neoplasma. 2017;64:641–54.
Article CAS PubMed Google Scholar
Gannett PM, Sura TP. An improved synthesis of 8-bromo-2′-deoxyguanosine. Synth Commun. 1993;23:1611–5.
Brancale A, McGuigan C, Andrei G, Snoeck R, De Clercq E, Balzarini J. Bicyclic nucleoside inhibitors of varicella-zoster virus (VZV): the effect of a terminal halogen substitution in the side-chain. Bioorg Med Chem Lett. 2000;10:1215–7.
Article CAS PubMed Google Scholar
Cuzzupe AN, Hutton CA, Lilly MJ, Mann RK, McRae KJ, Zammit SC, et al. Total synthesis of the epidermal growth factor inhibitor (-)-reveromycin B. J Org Chem. 2001;66:2382–93.
Article CAS PubMed Google Scholar
McBride BJ, Baldwin RM, Kerr JM, Wu J-L. A simple method for the preparation of 123I and 125I labeled iodobenzodiazepines. Int J Radiat Appl Instrum Part A Appl Radiat Isotopes. 1991;42:173–5.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
Article CAS PubMed Google Scholar
Cai B, Chang S, Tian Y, Zhen S. CRISPR/Cas9 for hepatitis B virus infection treatment. Immun Inflamm Dis. 2023;11: e866.
Article CAS PubMed PubMed Central Google Scholar
Yang YC, Yang HC. Recent progress and future prospective in HBV cure by CRISPR/Cas. Viruses. 2021;14(1):4.
Gorsuch CL, Nemec P, Yu M, Xu S, Han D, Smith J, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther. 2022;30:2909–22.
Article CAS PubMed PubMed Central Google Scholar
Jones DE, Vernon CA. Nucleophilic substitution in vinylic halides. Nature. 1955;176:791–2.
Article ADS CAS Google Scholar
Xie L. Inventor A novel iodine-containing antiviral agent. China patent ZL202011151673.9. 2020. https://www.qcc.com/zhuanliDetail/c0c32ae6ab39641ddca64010cb047cad.html.
Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444–8.
Article CAS PubMed PubMed Central Google Scholar
Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy - a review. EJNMMI Radiopharm Chem. 2019;4:27.
Article PubMed PubMed Central Google Scholar
Martinez MG, Boyd A, Combe E, Testoni B, Zoulim F. Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections. J Hepatol. 2021;75:706–17.
Article CAS PubMed Google Scholar
Panyutin IV, Sedelnikova OA, Bonner WM, Panyutin IG, Neumann RD. DNA damage produced by 125I-triplex-forming oligonucleotides as a measure of their successful delivery into cell nuclei. Ann N Y Acad Sci. 2005;1058:140–50.
Article ADS CAS PubMed Google Scholar
Chen Q, Chen H, Wang W, Liu J, Liu W, Ni P, et al. Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition. Eur J Pharm Sci. 2017;106:313–27.
Article CAS PubMed Google Scholar
Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2: 100112.
留言 (0)